Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Simon Everitt is active.

Publication


Featured researches published by Simon Everitt.


Bioorganic & Medicinal Chemistry Letters | 2009

The discovery of the potent aurora inhibitor MK-0457 (VX-680).

David Bebbington; Hayley Binch; Jean-Damien Charrier; Simon Everitt; Damien Fraysse; Julian Golec; David Kay; Ronald Knegtel; Chau Mak; Francesca Mazzei; Andrew Miller; Michael Mortimore; Michael O’Donnell; Sanjay Patel; Francoise Pierard; Joanne Pinder; John Pollard; Sharn Ramaya; Daniel Robinson; Alistair Rutherford; John Studley; James Westcott

The identification of a novel series of Aurora kinase inhibitors and exploitation of their SAR is described. Replacement of the initial quinazoline core with a pyrimidine scaffold and modification of substituents led to a series of very potent inhibitors of cellular proliferation. MK-0457 (VX-680) has been assessed in Phase II clinical trials in patients with treatment-refractory chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) containing the T315I mutation.


Archive | 2005

Azaindoles useful as inhibitors of JAK and other protein kinases

Francesco Salituro; Luc J. Farmer; Randy S. Bethiel; Edmund Harrington; Jeremy Green; John J. Court; Jon H. Come; David J. Lauffer; Alex Aronov; Hayley Binch; Dean Boyall; Jean-Damien Charrier; Simon Everitt; Damien Fraysse; Michael Mortimore; Francoise Pierard; Daniel Robinson; Jian Wang; Joanne Pinder; Tiansheng Wang; Albert Pierce


Archive | 2006

Aminopyrimidines useful as kinase inhibitors

Hayley Binch; Michael Mortimore; Damien Fraysse; Christopher John Davis; Michael O'donnell; Simon Everitt; Daniel Robinson; Joanne Pinder; Andrew Miller


Archive | 2003

Azinylaminoazoles as inhibitors of protein kinases

David Bebbington; Hayley Binch; Jean-Damien Charrier; Simon Everitt; Julian Golec; David Kay; Ronald Knegtel; Andrew Miller; Francoise Pierard


Archive | 2003

Azolylaminoazine as inhibitors of protein kinases

David Bebbington; Hayley Binch; Jean-Damien Charrier; Simon Everitt; Julian Golec; David Kay; Ronald Knegtel; Andrew Miller; Francoise Pierard


Archive | 2003

Azolylaminoazines as inhibitors of protein kinases

David Bebbington; Hayley Binch; Jean-Damien Charrier; Simon Everitt; Julian Golec; David Kay; Ronald Knegtel; Andrew Miller; Francoise Pierard


Archive | 2007

5-cyano-4- (pyrrolo [2,3B] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors

Michael Mortimore; Stephen Young; Simon Everitt; Ronald Knegtel; Joanne Pinder; Alistair Rutherford; Steven Durrant; Guy Brenchley; Jean Damien Charrier; Michael O'donnell


Archive | 2006

Benzimidazoles useful as inhibitors of protein kinases

Hayley Binch; Simon Everitt; Michael Mortimore; Daniel Robinson; Dean Stamos


Archive | 2004

Pyrazolopyrrole derivatives as protein kinase inhibitors

Hayley Binch; Simon Everitt; Francesca Mazzei; Daniel Robinson


Archive | 2013

Compounds useful as inhibitors of indoleamine 2,3-dioxygenase

Dean Boyall; Christopher John Davis; James Dodd; Simon Everitt; Andrew Miller; Peter Weber; James Westcott; Stephen Young; Luca Settimo

Collaboration


Dive into the Simon Everitt's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David Kay

Vertex Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge